Open Access Repository

Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study

Peacock, A ORCID: 0000-0002-5705-2026, Gisev, N, Memedovic, S, Larance, B, Brown, J, Cairns, R, Buckley, N, Farrell, M and Degenhardt, L 2020 , 'Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study' , Drug and Alcohol Dependence, vol. 206 , pp. 1-10 , doi: 10.1016/j.drugalcdep.2019.107697.

Full text not available from this repository.


Aims: A sustained-release formulation (SRF) of tapentadol has been marketed in Australia since February 2013.This study examined tapentadol SRF extra-medical use, attractiveness for extra-medical use, and associatedharms in Australia.Methods: This post-marketing study comprises analyses of Australian community sales data (2011–2017) foreleven pharmaceutical opioids (prescription and over-the-counter codeine disaggregated); calls to three poisonsinformation centres (covering five of the eight jurisdictions in Australia) related to pharmaceutical opioids andcoded by the centres as ‘misuse’ or ‘abuse’ (2011–2017); and interviews with people who inject drugs (n = 888)recruited as part of the Illicit Drug Reporting System (IDRS) from all Australian capital cities (2017).Results: Population-level availability of tapentadol SRF increased from market launch, comprising the sixthlargest market share of all opioid unit sales, and third greatest share in oral morphine equivalent milligrams sold,in December 2017. Lifetime tapentadol SRF use among the IDRS sample (n = 888) was low (1.5%; 95%CI0.9–2.5), with few reporting past-6 month non-prescribed use or injection. Non-fatal overdose following tapentadol use was self-reported by less than 1% (95%CI 0.1-0.8). Between 2013–2017, 1.1% (n = 25) of pharmaceutical opioid ‘misuse/abuse’ calls were related to tapentadol, and predominantly the SRF.Conclusions: Increasing utilisation of tapentadol sustained-release formulation was observed, along with indications of extra-medical use and harms associated with use, although on a smaller scale relative to otheropioids. These findings need to be interpreted in the context of the low level of exposure to tapentadol sustainedrelease formulation among the sentinel population of people who inject drugs.

Item Type: Article
Authors/Creators:Peacock, A and Gisev, N and Memedovic, S and Larance, B and Brown, J and Cairns, R and Buckley, N and Farrell, M and Degenhardt, L
Keywords: Tapentadol, opioid post-marketing surveillance, prescription drug diversion, overdose injecting drug use
Journal or Publication Title: Drug and Alcohol Dependence
Publisher: Elsevier Sci Ireland Ltd
ISSN: 0376-8716
DOI / ID Number: 10.1016/j.drugalcdep.2019.107697
Copyright Information:

Copyright 2019 Elsevier B.V.

Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page